Over the past decade, immune checkpoint inhibitors (ICI) have proven to be promising
agents in a number of solid tumor malignancies. Pembrolizumab and nivolumab are ICIs …

Despite the clinical success of T-cell checkpoint blockade, most patients with cancer still fail
to have durable responses to immunotherapy. The molecular mechanisms driving …

Immunotherapies are rapidly entering the clinic as approved treatments for diverse cancer
pathologies. Radiation therapy is an integral partner in cancer therapy, commonly as part of …

Abstract Although anti-PD-1/L1 and anti-CTLA-4 antibodies, the validated immune
checkpoint blockades, can elicit durable long-lasting antitumor immunity and improve the …

Overcoming tolerance to tumor-associated antigens remains a hurdle for cancer vaccine-
based immunotherapy. A strategy to enhance the anti-tumor immune response is the …

Tissue-resident memory T (T RM) cells are strategically positioned within the epithelial
layers of many tissues to provide enduring site-specific immunological memory. This unique …

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules
comprising (a) at least one moiety capable of specific binding to a target cell antigen,(b) a …

The present invention relates to antibodies (and fragments, variants, fusions and derivatives
thereof) with binding speci ficity for domain 2 of human CD137 which are capable of …

CD137, a member of the tumor necrosis factor receptor superfamily of cell surface proteins,
acts as a costimulatory receptor on T cells, natural killer cells, B cell subsets, and some …

4-1BB (CD137) is a T cell activating receptor belonging to the TNF receptor superfamily that
can betargeted by mAb to eradicate established tumours. 4-1BB is expressed on a multitude …